Your browser doesn't support javascript.
loading
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire, Julien; Anzala, Omu; Gazzard, Brian; Karita, Etienne; Bergin, Philip; Hayes, Peter; Kopycinski, Jakub; Omosa-Manyonyi, Gloria; Jackson, Akil; Bizimana, Jean; Farah, Bashir; Sayeed, Eddy; Parks, Christopher L; Inoue, Makoto; Hironaka, Takashi; Hara, Hiroto; Shu, Tsugumine; Matano, Tetsuro; Dally, Len; Barin, Burc; Park, Harriet; Gilmour, Jill; Lombardo, Angela; Excler, Jean-Louis; Fast, Patricia; Laufer, Dagna S; Cox, Josephine H.
Afiliação
  • Nyombayire J; Projet San Francisco, Kigali, Rwanda.
  • Anzala O; Kenya AIDS Vaccine Initiative Institute of Clinical Research, Nairobi.
  • Gazzard B; Chelsea and Westminster Healthcare NHS Foundation Trust.
  • Karita E; Projet San Francisco, Kigali, Rwanda.
  • Bergin P; Human Immunology Laboratory, International AIDS Vaccine Initiative, London, United Kingdom.
  • Hayes P; Human Immunology Laboratory, International AIDS Vaccine Initiative, London, United Kingdom.
  • Kopycinski J; Human Immunology Laboratory, International AIDS Vaccine Initiative, London, United Kingdom.
  • Omosa-Manyonyi G; Kenya AIDS Vaccine Initiative Institute of Clinical Research, Nairobi.
  • Jackson A; Chelsea and Westminster Healthcare NHS Foundation Trust.
  • Bizimana J; Projet San Francisco, Kigali, Rwanda.
  • Farah B; Kenya AIDS Vaccine Initiative Institute of Clinical Research, Nairobi.
  • Sayeed E; International AIDS Vaccine Initiative, New York, New York.
  • Parks CL; International AIDS Vaccine Initiative, New York, New York.
  • Inoue M; ID Pharma, Tsukuba.
  • Hironaka T; ID Pharma, Tsukuba.
  • Hara H; ID Pharma, Tsukuba.
  • Shu T; ID Pharma, Tsukuba.
  • Matano T; University of Tokyo.
  • Dally L; National Institute of Infectious Diseases, Tokyo, Japan.
  • Barin B; Emmes Corporation, Rockville, Maryland.
  • Park H; Emmes Corporation, Rockville, Maryland.
  • Gilmour J; International AIDS Vaccine Initiative, New York, New York.
  • Lombardo A; Human Immunology Laboratory, International AIDS Vaccine Initiative, London, United Kingdom.
  • Excler JL; International AIDS Vaccine Initiative, New York, New York.
  • Fast P; International AIDS Vaccine Initiative, New York, New York.
  • Laufer DS; International AIDS Vaccine Initiative, New York, New York.
  • Cox JH; International AIDS Vaccine Initiative, New York, New York.
J Infect Dis ; 215(1): 95-104, 2017 Jan 01.
Article em En | MEDLINE | ID: mdl-28077588
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Vacinas contra a AIDS / Linfócitos T CD8-Positivos / Vacinas de DNA / Vírus Sendai Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged País como assunto: Africa / Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Vacinas contra a AIDS / Linfócitos T CD8-Positivos / Vacinas de DNA / Vírus Sendai Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged País como assunto: Africa / Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article